The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases

Compositions comprising bacterial strains

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

Polypeptide and immune modulation

Biomarkers and methods for predicting the risk of a disease related to microbiota, in particular colorectal cancer (CRC), are provided.

Biomarkers for colorectal cancer

Disclosed herein are compositions that have substantially purified Christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of Christensenellaceae bacteria, such as Christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity, and reduce a high body mass index (BMI), and can also treat or prevent conditions correlating with excess weight and fat and a high BMI, such as insulin sensitivity, metabolic syndrome, excess adiposity, and diabetes.

Modulation of fat storage in a subject by altering population levels of christensenellaceae in the GI tract

The present invention relates to a biomarker for risk prediction or diagnosis of metabolic and inflammatory diseases, and use thereof. The biomarker is formulated to detect a group of microorganisms consisting of Akkermansia muciniphila, Bacteroides spp., Eubacterium spp., Roseburia spp., Methanobrevibacter smithii, Methanosphaera stadtmanae, Ruminococcus obeum, and Phascolarctobacterium.

Early diagnosis of obesity-related diseases using changes in the gut microbial community structure and function

Biomarkers for diabetes and usages thereof are provided. And the biomarkers are nucleotides having polynucleotide sequences defined in SEQ ID NOs: 1-50.

Biomarkers for Diabetes and Usages Thereof

Provided are biomarkers and methods for predicting the risk of a disease related to microbes, in particular obesity or related diseases.

Biomarkers for obesity related diseases

Biomarkers for rheumatoid arthritis (RA) are described. RA-associated metagenomic linkage groups (MLGs) have been identified and validated in gut and oral microbiotas. These MLGs are used in systems, methods and products for identifying a subject suffering from RA or having risk of developing RA, monitoring the efficacy of an RA treatment in a subject, or selecting or modifying a treatment for an RA patient.

Qiang Feng

Papers

Biomarkers for Diabetes and Usages Thereof

Biomarkers for obesity related diseases

Biomarkers for rheumatoid arthritis and usage thereof